Top

Journal of Radiation Oncology

Published in:

01-12-2017 | Original Research

Active monitoring in non-invasive breast cancer: insight gained from a large national database

Authors: Daniel M. Trifiletti, Surbhi Grover, Bertram W. Maidment III, Timothy N. Showalter, Shayna L. Showalter

Published in: Journal of Radiation Oncology | Issue 4/2017

Abstract

Objectives

The objective was to evaluate women diagnosed with ductal carcinoma in situ (DCIS) preoperatively and elucidate factors, including time from biopsy to excision, associated with invasive disease found on final pathology (underestimation).

Methods

The National Cancer Database was queried for women with preoperative DCIS receiving lumpectomy/mastectomy from 1998 to 2012 and investigated for factors associated with underestimation (invasive disease in the breast/nodes on excision).

Results

One hundred fifty-six thousand five hundred thirty-five women met inclusion criteria and 10.8% had underestimation of disease. 9.1% had invasive disease in the breast alone, 0.4% had nodal disease despite only DCIS in the breast, and 1.4% had both invasive disease in the breast and the axillary nodes. The adjusted risk of underestimation of invasive disease increased steadily with more time from biopsy to surgery (p < 0.001), as did the adjusted risk nodal disease (p < 0.001).

Conclusions

Several presurgical findings can predict for occult-invasive breast cancer including time from diagnosis to definitive surgery.

Ryerson AB, Eheman CR, Altekruse SF, et al (2016) Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer

Harding C, Pompei F, Burmistrov D et al (2015) Breast cancer screening, incidence, and mortality across US counties. JAMA Intern Med 175:1483–1489CrossRefPubMed

Esserman LJ, Thompson IM, Reid B et al (2014) Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 15:e234–e242CrossRefPubMedPubMedCentral

National Comprehensive Cancer Network Clinical Practice Guidelines: breast cancer v 2.2016, available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf, Accessed 1 Dec 2016

Prigerson HG, Bao Y, Shah MA et al (2015) Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 1:778–784CrossRefPubMedPubMedCentral

Letrozole in treating postmenopausal women with ductal carcinoma in situ (ClinicalTrials.gov Identifier NCT01439711), available at: https://clinicaltrials.gov/ct2/show/NCT01439711, Accessed 15 March 2016

Ryser MD, Worni M, Turner EL et al (2016) Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis. J Natl Cancer Inst 108:djv372CrossRefPubMed

Brennan ME, Turner RM, Ciatto S et al (2011) Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 260:119–128CrossRefPubMed

American College of Surgeons, National Cancer Data Base, available at: https://www.facs.org/quality-programs/cancer/ncdb, Accessed 9 April 2015

10.

American College of Surgeons National Cancer Database: patient user file data dictionary items, available at: http://ncdbpuf.facs.org/?q=node/259, Accessed 15 April 2015

11.

Yen TW, Hunt KK, Ross MI et al (2005) Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 200:516–526CrossRefPubMed

12.

Dillon MF, McDermott EW, Quinn CM et al (2006) Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only. J Surg Oncol 93:559–563CrossRefPubMed

13.

Goyal A, Douglas-Jones A, Monypenny I et al (2006) Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res Treat 98:311–314CrossRefPubMed

14.

Maffuz A, Barroso-Bravo S, Najera I et al (2006) Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ. J Exp Clin Cancer Res 25:223–227PubMed

15.

Meijnen P, Oldenburg HS, Loo CE et al (2007) Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg 94:952–956CrossRefPubMed

16.

Moran CJ, Kell MR, Flanagan FL et al (2007) Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. Am J Surg 194:172–175CrossRefPubMed

17.

Rutstein LA, Johnson RR, Poller WR et al (2007) Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ. Breast J 13:251–257CrossRefPubMed

18.

Dominguez FJ, Golshan M, Black DM et al (2008) Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol 15:268–273CrossRefPubMed

19.

Schneider C, Trocha S, McKinley B et al (2010) The use of sentinel lymph node biopsy in ductal carcinoma in situ. Am Surg 76:943–946PubMed

20.

Han JS, Molberg KH, Sarode V (2011) Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J 17:223–229CrossRefPubMed

21.

Sanders ME, Schuyler PA, Dupont WD et al (2005) The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103:2481–2484CrossRefPubMed

22.

Francis A, Fallowfield L, Rea D (2015) The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol 27:6–8CrossRef

23.

Francis A, Thomas J, Fallowfield L et al (2015) Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer 51:2296–2303CrossRefPubMed

24.

Pilewskie M, Olcese C, Patil S et al (2016) Women with low-risk DCIS eligible for the LORIS trial after complete surgical excision: how low is their risk after standard therapy? Ann Surg Oncol 23:4253–4261CrossRefPubMed

25.

Alvarado M, Carter DL, Guenther JM et al (2015) The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: a prospective clinical utility assessment of the 12-gene DCIS score result. J Surg Oncol 111:935–940CrossRefPubMed

26.

Rakovitch E, Nofech-Mozes S, Hanna W et al (2015) A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152:389–398CrossRefPubMedPubMedCentral

Title: Active monitoring in non-invasive breast cancer: insight gained from a large national database
Authors: Daniel M. Trifiletti
Surbhi Grover
Bertram W. Maidment III
Timothy N. Showalter
Shayna L. Showalter
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Radiation Oncology / Issue 4/2017
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-017-0322-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2017

Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation

Liver stereotactic radiotherapy (SRT) with functional treatment planning for patients with intermediate stage hepatocellular carcinoma (HCC)

Hemostatic radiotherapy in advanced bladder cancer: a single-institution experience

Stereotactic ablative radiotherapy with targeted MRI-defined gross tumor dose escalation for prostate cancer: dosimetric feasibility and interfraction robustness

Analysis of treatment effectiveness and complications associated with MammoSite™ breast brachytherapy in patients treated at a single institution

Intratumoral treatment with radioactive beta-emitting microparticles: a systematic review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer